Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Analysis (n=294) notes improvement in health related quality of life with pembrolizumab (PM) vs. chemotherapy (between-group least squares mean difference in scores 8.96;p=0.0002).Median time to deterioration was longer with PM for physical & social functioning and fatigue scores

The Lancet Oncology